Search Within

Urvi A Shah

Formats
  1. Meeting Abstract (136)
  2. Journal Article (35)
  3. Research Letter (12)
  4. Review (9)
  5. Correspondence (3)
  6. Editorial (2)
  7. Book Section (1)
Groups
  1. CTCR Scholars (198)
  2. Department of Medicine (198)
  3. Hematologic Malignancies, Division of (198)
  4. Center for Hematologic Malignancies (153)
  5. Myeloma (152)
  6. Hematologic Malignancies Research (147)

More Groups

People
  1. Alexander Lesokhin (143)
  2. Sham Mailankody (138)
  3. Malin Hultcrantz (132)
  4. Neha Korde (130)
  5. Hani Hassoun (129)
  6. Carlyn Rose Tan (119)

More People

Years
  1. 2025 (5)
  2. 2024 (49)
  3. 2023 (44)
  4. 2022 (44)
  5. 2021 (16)
  6. 2020 (20)

More Years

Publications
  1. Blood (76)
  2. Clinical Lymphoma, Myeloma and Leukemia (42)
  3. Journal of Clinical Oncology (15)
  4. Blood Cancer Journal (8)
  5. Blood Advances (7)
  6. Biology of Blood and Marrow Transplantation (4)

More Publications

Publishers
  1. American Society of Hematology (83)
  2. Elsevier Inc. (51)
  3. American Society of Clinical Oncology (15)
  4. Nature Publishing Group (13)
  5. American Association for Cancer Research (5)
  6. American Medical Association (4)

More Publishers

Results (198)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing
    Research Letter

    Tan, C. R.; Wang, A.; Nemirovsky, D.; Derkach, A.; Shekarkhand, T.; Hamadeh, I.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: An updated analysis
    Journal Article

    Jurgens, E. M.; Firestone, R. S.; Chaudhari, J.; Hosszu, K.; Devlin, S. M.; Shah, U. A.; Landa, J.; McAvoy, D. P.; Lesokhin, A. M.; Korde, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Evaluating serum free light chain ratio as a biomarker in multiple myeloma
    Journal Article

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C. R.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): Results from a randomised, open-label, phase 3 trial
    Journal Article

    Mina, R.; Mylin, A. K.; Yokoyama, H.; Magen, H.; Alsdorf, W.; Minnema, M. C.; Shune, L.; Isufi, I.; Harrison, S. J.; Shah, U. A.; more...
    The Lancet Haematology (2025)

    Fulltext@MSK | Save
  • Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes
    Journal Article

    Valtis, Y. K.; Devlin, S.; Shouval, R.; Rejeski, K.; Corona, M.; De Abia, A. L.; Rivas-Delgado, A.; Luttwak, E.; Cassanello, G.; Landego, I.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Belantamab mafodotin, nirogacestat and pomalidomide for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; Hashmi, H.; Maclachlan, K. H.; Rajeeve, S.; Shah, U. A.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Rajeeve, S.; Costa, B. A.; Jurgens, E. M.; Nishimura, N.; Farzana, T.; Firestone, R. S.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Racial differences in proportion of myeloma cases attributable to modifiable risk factors in the United States, 2016-21
    Meeting Abstract

    Anuraj, A.; Rath, D.; Derkach, A.; Usmani, S. Z.; Shah, U. A.
    Blood (2024)

    Fulltext@MSK | Save
  • Initial results of a phase 1 first-in-human study of cemsidomide (CFT7455), a novel MonoDACTM degrader, with dexamethasone in patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Dhakal, B.; Yee, A. J.; Richardson, P. G.; Ailawadhi, S.; Chhabra, S.; Muchtar, E.; Berdeja, J. G.; Richard, S.; Matous, J.; Shah, U. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma- Interim efficacy results of a randomized clinical trial
    Meeting Abstract

    Rajeeve, S.; Derkach, A.; Devlin, S. M.; Santos, J.; Przemielewska, A.; Sood, T.; Maclachlan, K. H.; Hashmi, H.; Tan, C. R.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save